Firm Events
District Court vs. PTAB: Strategic Forum Selection in Life Sciences Patent Disputes
December 10, 2026 | 12:00 PM – 1:00 PM ET
On October 22, 2026, the Civil Division of the U.S. Department of Justice (DOJ), in partnership with the Department of Health and Human Services (HHS), announced the Healthcare False Claims Act Self-Disclosure Pilot Program (FCA SDPP or Pilot Program). The Pilot Program will run for six months and is intended to provide “a clear and predictable pathway” to resolve potential civil liability under the FCA. It is also designed for issues that arise under HHS administrative authorities, including revocation of enrollment in Medicare, permissive exclusion for false or improper claims, and permissive exclusion based on fraud and kickbacks or other prohibited activities. The DOJ and HHS made clear that the Pilot Program is for “legitimate American healthcare businesses endeavoring to quickly and cooperatively resolve prior misconduct and move forward with a clean slate.” In contrast, illegitimate businesses that knowingly exploit the United States do not qualify for the Pilot Program.
The hallmark of the Pilot Program is voluntary self-disclosure. The steps required to participate and the benefits for the disclosing company are outlined below. Given that the government recently rolled out the program, there are no real-world examples of how the program would apply in practice, or which companies stand to benefit the most by participating. The DOJ offered two hypothetical examples in its press release of how the Pilot Program would operate. The examples offer insight into the kinds of scenarios where utilization of the Pilot Program is most advantageous.
In the first example, a hospital that realized it had not been complying with Medicare’s 14-day rule prepared a sample chart review for the relevant time period. In doing so, the hospital identified an error rate that it then extrapolated over the population of claims. The hospital produced both the chart review results and information about the sampling and extrapolation methodologies to the government. Based on this example, it appears that run-of-the-mill, easily quantifiable rule violations are well suited for the Pilot Program. Whether that is true for FCA or federal rule violations that involve multiple components, and more discretion on the part of the disclosing company, is less clear.
In the second example, a company that acquired a health care company learned that the health care company engaged in conduct that could establish FCA liability through the Anti-Kickback Statute (AKS). The acquiring company then produced documents of the payments and associated revenue of the health care company for the government to review. By doing so, the acquiring company avoided damages based on the claim-paid amounts. Instead, the government calculated the company’s repayment based on the consideration of the amount of the remuneration, the revenue derived from the disclosed conduct, and the absence of aggravating factors such as patient harm. As a result, companies going through a merger, acquisition, or the like stand to benefit by self-disclosing through the Pilot Program. Companies may reduce their overall exposure and resolve potential violations more efficiently, without the potential for costly, years-long litigation.
Health care providers, suppliers, manufacturers, payors, and related entities that furnish, arrange for, manufacture, distribute, insure, administer, or bill for items or services paid for, directly or indirectly, by HHS federal health care programs are eligible to participate in the Pilot Program. Critically, the disclosure must involve a potential FCA violation previously unknown to the federal government. If the government is already aware of the conduct, the company may still earn self-disclosure and cooperation credit under existing DOJ policy (Justice Manual Section 4-4.112) but will not be eligible for a Pilot Program resolution.
Submissions must be made to FCA-SDPP@usdoj.gov by 11:59 p.m. on April 22, 2027, and late or partial submissions will not be accepted or reviewed.
A qualifying self-disclosure must be complete at the time of submission and must:
While DOJ describes the Pilot Program as building on “longstanding Department principles,” several features mark a meaningful shift in how civil health care fraud matters may be resolved:
The Pilot Program covers civil liability only. A company seeking to self-disclose potential criminal health care conduct must disclose it to DOJ’s National Fraud Enforcement Division under that Division’s coordination policy with HHS-OIG. A company that has already made a voluntary self-disclosure of criminal matters to the Fraud Division under the Corporate Enforcement and Voluntary Self-Disclosure Policy (CEP), which the Criminal Division revised in May 2025 to offer a clearer path to declination, need not make a duplicative Pilot Program submission. Where such a company also seeks a civil FCA release, DOJ will request supplementation of its Fraud Division disclosure only to the extent necessary. Companies should therefore assess at the outset whether conduct carries potential criminal exposure, because that assessment will determine the appropriate disclosure channel and may affect charging outcomes.
Troutman Pepper Locke’s White Collar Litigation + Investigations Practice Group is closely monitoring DOJ’s evolving self-disclosure policies and health care fraud enforcement priorities. If you have questions about how the Pilot Program may affect your business or wish to evaluate whether a self-disclosure is appropriate, contact a member of our White Collar Litigation + Investigations team, whose attorneys advise on False Claims Act matters, including internal investigations and compliance program enhancement.
Emily Rockwell also contributed to this article. She is not licensed to practice law in any jurisdiction; bar admission pending.
This just in
Firm Events
District Court vs. PTAB: Strategic Forum Selection in Life Sciences Patent Disputes
December 10, 2026 | 12:00 PM – 1:00 PM ET
Speaking Engagements
Performance on Trial: The Construction Manager’s Standard of Care Examined from All Angles
December 2, 2026 | 4:15 PM – 5:30 PM ET
The Hyatt Regency Huntington Beach
Huntington Beach, CA
Speaking Engagements
ACI’s 31st Annual Conference on Drug & Medical Device Litigation – 2026
December 2 – 3, 2026
New York Marriott Marquis
1535 Broadway, New York, NY 10036
Speaking Engagements
Entering the Defense Market: USA, Canada, Ukraine, UK, Germany, Poland
November 19, 2026 | 3:00 PM – 5:00 PM CT
Virtual